Navigation Links
Valeant Pharmaceuticals Announces New Management Appointments

MONTREAL, Nov. 28, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.  Mr. Weldon will assume the role of Executive Vice President/Company Group Chairman where he will lead the U.S. Dermatology operations, including prescription dermatology, aesthetics and podiatry. Mr. Weldon will be relocating to Arizona where these operations will be headquartered.  Mr. Hanson will relocate to New Jersey where he will assume the role of Executive Vice President/Company Group Chairman and lead certain U.S and international businesses and functions to be named later.  In addition, Vince Ippolito will be appointed Senior Vice President, General Manager, Aesthetics and Justin Smith will be appointed Senior Vice President, General Manager U.S. Rx Dermatology and both will report to Ryan Weldon in Scottsdale, AZ.  Mr. Ippolito and Mr. Smith have each held various sales and marketing leadership positions at Medicis Pharmaceutical Corporation (NYSE: MRX). These changes will be effective upon the close of Valeant's acquisition of Medicis, currently anticipated to occur on December 11, 2012.

"The Board of Directors and I are pleased to add such experienced candidates to the Valeant management team," said J. Michael Pearson, chairman and chief executive officer.  "These individuals have demonstrated exceptional operating performance at their respective companies and business units and I believe they are the right candidates to continue Valeant's growth and success in the future. We expect to be able to announce more management announcements around the time of closing."

Ryan Weldon has served as Vice President & General Manager, Aesthetics since December 2011 and Vice President & General Manager, Neurology & Other since January 2010. Mr. Weldon joined Valeant in 2008 after working for McKinsey & Co. and Johnson & Johnson.

Jason Hanson has served as Executive Vice President, Chief Operating Officer of Medicis Pharmaceutical Corporation since July 2010, and as Executive Vice President since 2006. Mr. Hanson joined Medicis in 2006 and was appointed to the position of Executive Vice President, General Counsel, and Corporate Secretary. From April 2004 to July 2006, Mr. Hanson served as General Counsel for GE Healthcare Technologies, a global business specializing in medical imaging, information technology and other durable medical equipment and services, where he was responsible for the global legal affairs of GE Healthcare Technologies and a member of the company's senior management team.

Vince Ippolito has been with Medicis for ten years where he most recently served as Executive Vice President, Sales and Marketing. During his tenure at Medicis, he has helped launch more than ten new products, including LOPROX® Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®, ZIANA® and DYSPORT®. Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG.

Justin Smith has been with Medicis for fifteen years where he most recently served as Senior Vice President, Marketing for both dermatology and aesthetics products.  Most recently, Mr. Smith spearheaded Medicis' access solutions strategy and was responsible for launching SOLODYN®.  He also held senior positions in sales management. 

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at

Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements relate to, among other things, the closing of the Medicis transaction and the future roles of certain management. Forward-looking statements can generally be identified by the use of words such as "believe," "anticipate," "expect," "estimate," "intend," "continue," "plan," "project," "will," "may," "should," "could," "would," "target," "potential," and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the satisfaction of customary closing conditions with respect to the closing of the Medicis transaction, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators. 

Contact Information: 
Laurie W. Little 


SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
2. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
3. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
4. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
5. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
6. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
7. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
8. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
9. Valeant Pharmaceuticals To Syndicate Incremental Loans
10. Valeant Pharmaceuticals Announces Management Change
11. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
Post Your Comments:
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
(Date:12/1/2015)... , Dec. 1, 2015 Pharma Tech ... Top 10 Clinical Data Management Solution Providers - ... a distinguished panel comprising CEOs, CIOs, VCs, analysts, and ... the illustrious list of top 10 clinical data management ... article on pages 14 and 36 respectively). ...
(Date:12/1/2015)... de diciembre de 2015  AccuTEC Blades, ... de precisión, develó hoy un nuevo logo ... marca. El nuevo logo destaca la experiencia ... ingeniería de productos con cuchillas donde "el ... --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- InstantLabs ... company’s growing product line of food safety and seafood fraud prevention tools. , ... – allow InstantLabs to offer fast, reliable species identification for the four most ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a thing of ... greater among Millennials (a whopping one in three aged 18 to 25 is inked). ... dissatisfied with their ink. In fact, RealSelf , the world’s largest community for ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance ... imaging is the focus of numerous abstracts accepted for presentation here, at the ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging ... owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating ... North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
Breaking Medicine News(10 mins):